What is ViewsML?
ViewsML operates at the intersection of deep learning and oncology, providing advanced AI solutions for cancer treatment, diagnosis, and research. By focusing on biomarker detection and precision medicine, the firm enhances clinical workflows through virtual diagnostics that deliver actionable results in seconds. This technological capability significantly reduces the time and cost burdens associated with traditional diagnostic methods. The company serves a diverse clientele, including preclinical, translational, and clinical research organizations, positioning itself as a critical infrastructure provider for improving patient outcomes and accelerating project turnaround times across various therapeutic areas.
How much funding has ViewsML raised?
ViewsML has raised a total of $4.9M across 1 funding round:
Seed
$4.9M
Seed (2026): $4.9M with participation from RiSC Capital, Wittington Ventures, Continuum Ventures, Debiopharm, and Wutif
Key Investors in ViewsML
RiSC Capital
A Canadian deep tech venture capital fund specializing in early-stage investments, providing strategic guidance and technical expertise to foster innovation.
Continuum Ventures
An early-stage venture capital firm focused on Healthtech and TechBio, dedicated to transforming healthcare through preventative, AI-driven solutions.
Debiopharm
The investment division of the Debiopharm Group, focusing on private equity and strategic capital deployment to support long-term financial and scientific growth.
What's next for ViewsML?
With this major enterprise-level funding, ViewsML is well-positioned to scale its operations and deepen its penetration into the global healthtech market. The strategic capital will likely be deployed to expand its biomarker detection capabilities and refine its deep learning models for broader therapeutic applications. As the company transitions from its current growth phase, the focus will shift toward commercializing its virtual diagnostic platform and strengthening partnerships with contract research organizations. By leveraging the expertise of its backers, ViewsML aims to solidify its market position as a leader in the digital transformation of oncology, ultimately driving the industry toward a more data-centric and preventative model of patient care.
See full ViewsML company page
